GENELABS TECHNOLOGIES INC /CA
GNLBTicker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Insider trading at GENELABS TECHNOLOGIES INC /CA (GNLB) refers to stock transactions executed by corporate insiders—officers, directors, and shareholders owning more than 10% of the company. Over the past 90 days, 10 insiders have filed 72 transactions totaling $8.6M in trading activity. The most active insider is Stanley Morgan (Executive), contributing $8.5M across 35 transactions.
GENELABS TECHNOLOGIES INC /CA insiders are currently net sellers of GNLB stock, showing bearish sentiment over the past 90 days. Total sales of $7.6M outpace purchases of $987.8K, creating a net outflow of $6.6M.
GENELABS TECHNOLOGIES INC /CA has 10 active insiders who have filed SEC Form 4 transactions in the past 90 days. Stanley Morgan (Executive) leads with 35 transactions totaling $8.5M. Irene A. Chow (Executive) follows with 9 transactions worth $101.1K. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.
The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. GENELABS TECHNOLOGIES INC /CA's current score of 12/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.
The most recent insider transaction occurred on Jan 7, 2009, when Clinton Webb Daniel (Executive) disposed of 14,875 shares at $1.30 per share for $19.3K. This appears to be a discretionary trade.
Based on SEC Form 4 filings from the past 90 days, GNLB insider trading sentiment is currently bearish with an Alignment Score of 12/100. The negative net flow of $6.6M shows more selling than buying. However, 0% of recent transactions are 10b5-1 scheduled trades.
SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like GENELABS TECHNOLOGIES INC /CA. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At GNLB, we track all Form 4 filings—currently showing 72 transactions from 10 insiders over 90 days.
A 10b5-1 plan allows GENELABS TECHNOLOGIES INC /CA executives to pre-schedule stock sales when they don't possess material non-public information. At GNLB, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at GNLB appears discretionary, making insider signals more meaningful.
You can monitor GENELABS TECHNOLOGIES INC /CA (GNLB) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 10 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.
Insider trading at GENELABS TECHNOLOGIES INC /CA (GNLB) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of shares. These individuals must report trades to the SEC within two business days. Currently, 10 insiders are actively trading GNLB stock, having executed 72 transactions in the past 90 days. The most active insider is Stanley Morgan (Executive), with 35 transactions totaling $8.5M.
Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. GENELABS TECHNOLOGIES INC /CA's current score of 12/100 indicates bearish sentiment with significant insider selling pressure. This is calculated from $987.8K in purchases versus $7.6M in sales over 90 days, resulting in a net flow of -$6.6M.
SEC Form 4 filings are mandatory reports that GENELABS TECHNOLOGIES INC /CA insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At GNLB, the most common type is "S" with 20 occurrences. The most recent Form 4 was filed on Jan 7, 2009 by Clinton Webb Daniel.
Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At GENELABS TECHNOLOGIES INC /CA, approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at GNLB represents discretionary decisions with more informational value.
Track every insider move.
Before the market reacts.
Set alerts for GENELABS TECHNOLOGIES INC /CA and 40,000+ other insiders.